Boehringer beats Bayer to the regulators
The FDA will rule on a low dose of zongertinib in the summer.
FDA red and green lights: January 2025
AstraZeneca bags three of the month’s four oncology approvals.
Vir shows up Sanofi
Two masked bispecific antibodies, licensed for $100m, produce promising early data.
FDA red and green lights: November 2024
Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.
Targeted lung cancer niche sees a German pharma battle
But could toxicity be holding back filing plans?
Regeneron keeps up its co-stimulatory crusade
The company’s CD38 x CD28 MAb is among recent clinical trial entrants.
The month ahead: November’s upcoming events
Conferences ramp up, and ASH abstracts near.
